About Aditx Therapeutics
Aditx Therapeutics is a company based in Loma Linda (United States) founded in 2017. Aditx Therapeutics has raised $109.8 thousand across 4 funding rounds. The company has 26 employees as of December 31, 2024. Aditx Therapeutics has completed 5 acquisitions, including AiPharma, Aipharma and Appili Therapeutics. Aditx Therapeutics offers products and services including Adimune, Pearsanta, Adivue, Appili, and Evofem. Aditx Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Loma Linda, United States
- Employees 26 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aditxt, Inc.
-
Annual Revenue
$133.99 K (USD)-79.23as on Dec 31, 2024
-
Net Profit
-$34.45 M (USD)-6.38as on Dec 31, 2024
-
EBITDA
-$27.25 M (USD)-6.77as on Dec 31, 2024
-
Total Equity Funding
$109.8 K (USD)
in 4 rounds
-
Latest Funding Round
$6 M (USD), Post-IPO
Dec 29, 2023
-
Investors
Not available
-
Employee Count
26
as on Dec 31, 2024
-
Investments & Acquisitions
AiPharma
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aditx Therapeutics
Aditx Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ADTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aditx Therapeutics
Aditx Therapeutics offers a comprehensive portfolio of products and services, including Adimune, Pearsanta, Adivue, Appili, and Evofem.
Focuses on addressing autoimmunity issues through innovative health solutions.
Develops tools for early cancer detection in health diagnostics.
Targets neurological conditions with diagnostic innovations.
Plans programs for managing infectious disease challenges.
Focuses on reproductive health innovations and treatments.
People of Aditx Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Aditx Therapeutics
Aditx Therapeutics has successfully raised a total of $109.8K across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Aditx Therapeutics
Aditx Therapeutics has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include AiPharma, Aipharma and Appili Therapeutics.
Investment portfolio details for Aditx Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Offers proteomics assays for physician support and therapeutic development.
|
Locked | Locked | 2024 | Locked | |
|
Distributor of diversified pharmaceutical products
|
Locked | Locked | 2021 | Locked | |
|
Pharmaceutical drugs are manufactured by AiPharma in Dubai.
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Aditx Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Aditx Therapeutics
Detailed financials for Aditx Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aditx Therapeutics Comparisons
Peer comparison for Aditx Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aditx Therapeutics
Aditx Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
Detailed competitors of Aditx Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aditx Therapeutics
Complete news archive for Aditx Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aditx Therapeutics
Aditx Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Aditx Therapeutics is headquartered in Loma Linda, United States. It is registered at Loma Linda, California, United States.
Aditx Therapeutics is a funded company, having raised a total of $109.8K across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Aditx Therapeutics is 26.
Annual revenue of Aditx Therapeutics is $133.99K as on Dec 31, 2024.
Aditx Therapeutics was founded in 2017 and is based in Loma Linda, United States. Operations focus on the biotechnology sector, where a technology platform is commercialized to deliver personalized profiles of the immune system. Immune monitoring solutions are supplied to the medical community, with the AditxtScore product developed specifically for Covid-19 applications. The companys domain is aditxt.com, and key personnel include Amro Albanna.
Aditx Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Aditx Therapeutics offers Adimune, Pearsanta, Adivue, Appili, and Evofem.
Yes, Aditx Therapeutics is publicly traded on NASDAQ under the ticker symbol ADTX.
Aditx Therapeutics has made 5 acquisitions, including AiPharma, Aipharma, and Appili Therapeutics.
The ticker symbol of Aditx Therapeutics is ADTX on NASDAQ.